A short review on toxin-induced animal models of Huntington’s disease
Huntington’s disease animal models review
Keywords:
Animal Models, Huntington’s Disease, Transgenic Model, 3-Nitropropionic Acid, Quinolinic AcidAbstract
BACKGROUND: Huntington's disease (HD) is a neurodegenerative heredity motor and cognitional disorder. Different animal models of HD have been provided to study the different aspects of the disease such as pathophysiology and treatment and also the cure. Scientists need to choose the appropriate model for their goals, but it is often difficult because of the constraints. The low prevalence of HD often makes human studies impossible. For this reason, the availability of different animal models will be very helpful.
METHODS: To write this article, we searched “Huntington's Disease”, “Huntington's Disease with Animal Models”, and “Toxin-Induced Models with Huntington's disease”, and then “3-Nitropropionic Acid”, “Malonic Acid”, “Kainic Acid”, “Quinolinic Acid”, all in combination with Huntington's Disease Animal Model in medical databases (such as PubMed, Scopus, etc.); then, all papers were reviewed, excluded , and summarized as text and tables .
RESULTS: Animal models of HD are divided into two general categories: toxin-induced models and genetic models. Although it is clear that the genetic models are more compatible with HD, it is important to study all others to find the best models according to your research goals. 3-nitropropionic acid (3-NPA), malonic acid (MA), kainic acid (KA), and quinolinic acid (QA) are toxins used in past studies to induce different aspects of HD.
CONCLUSION: 3-NPA model is the most frequent model used for this purpose and after that, QA has been used more, but the other two models are less commonly used today. There are several different doses and routes of administration to induct toxin-induced HD models in different animals and for different purposes, and this diversity is misleading. That is why we have tried to compile all these models for researchers.References
Roos RA. Huntington's disease: a clinical review. Orphanet J Rare Dis. 2010; 5: 40.
MacDonald ME, Ambrose CM, Duyao MP, Myers RH, Lin C, Srinidhi L, et al. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell. 1993; 72(6): 971-83.
Nakamura S. Huntington's disease--advances in gene mapping. Nihon Rinsho. 1993; 51(9): 2481-7. [In Japanese].
Bates G, Tabrizi S, Jones L, editors. Huntington’s Disease. 4th ed. New York: Oxford University Press; 2014.
Hayden MR. Huntington’s chorea. London, UK: Springer London; 1981.
Kaur N, Jamwal S, Gill HK, Bansal PK. Animal Models of Huntington’s Disease. In: Bansal PK, Deshmukh R, editors. Animal Models of Neurological Disorders: Principle and Working Procedure for Animal Models of Neurological Disorders. Singapore: Springer Singapore; 2017. p. 43-57.
Brouillet E, Condé F, Beal MF, Hantraye P. Replicating Huntington's disease phenotype in experimental animals. Prog Neurobiol. 1999; 59(5): 427-68.
Menalled L, Brunner D. Animal models of Huntington's disease for translation to the clinic: best practices. Mov Disord. 2014; 29(11): 1375-90.
Pouladi MA, Morton AJ, Hayden MR. Choosing an animal model for the study of Huntington's disease. Nat Rev Neurosci. 2013; 14(10): 708-21.
Ramaswamy S, McBride JL, Kordower JH. Animal models of Huntington's disease. Ilar j. 2007; 48(4): 356-73.
Wei D-L, Chang S-C, Lin S-C, Doong M-L, Jong S-C. Production of 3-nitropropionic acid byArthrinium species. Curr Microbiol. 1994; 28(1): 1-5.
Borlongan CV, Koutouzis TK, Sanberg PR. 3-Nitropropionic acid animal model and Huntington's disease. Neurosci Biobehav Rev. 1997; 21(3): 289-93.
Pelegrí C, Duran-Vilaregut J, del Valle J, Crespo-Biel N, Ferrer I, Pallàs M, et al. Cell cycle activation in striatal neurons from Huntington's disease patients and rats treated with 3-nitropropionic acid. Int J Dev Neurosci. 2008; 26(7): 665-71.
Beal MF, Brouillet E, Jenkins BG, Ferrante RJ, Kowall NW, Miller JM, et al. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J Neurosci. 1993; 13(10): 4181-92.
Brouillet E, Jacquard C, Bizat N, Blum D. 3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease. J Neurochem. 2005; 95(6): 1521-40.
Stavrovskaya A, Yamshchikova N, Ol’shanskiy A, Konovalova E, Illarioshkin S. Transplantation of neuronal precursors derived from induced pluripotent stem cells into the striatum of rats with the toxin-induced model of huntington’s disease. Hum Physiol. 2017; 43(8): 881-5.
Gould DH, Gustine DL. Basal ganglia degeneration, myelin alterations, and enzyme inhibition induced in mice by the plant toxin 3-nitropropanoic acid. Neuropathol Appl Neurobiol. 1982; 8(5): 377-93.
Hamilton BF, Gould DH. Nature and distribution of brain lesions in rats intoxicated with 3-nitropropionic acid: a type of hypoxic (energy deficient) brain damage. Acta Neuropathol. 1987; 72(3): 286-97.
Guyot MC, Hantraye P, Dolan R, Palfi S, Maziére M, Brouillet E. Quantifiable bradykinesia, gait abnormalities and Huntington's disease-like striatal lesions in rats chronically treated with 3-nitropropionic acid. Neuroscience. 1997; 79(1): 45-56.
Nishino H, Kumazaki M, Fukuda A, Fujimoto I, Shimano Y, Hida H, et al. Acute 3-nitropropionic acid intoxication induces striatal astrocytic cell death and dysfunction of the blood-brain barrier: involvement of dopamine toxicity. Neurosci Res. 1997; 27(4): 343-55.
Shear DA, Dong J, Gundy CD, Haik-Creguer KL, Dunbar GL. Comparison of intrastriatal injections of quinolinic acid and 3-nitropropionic acid for use in animal models of Huntington's disease. Prog Neuropsychopharmacol Biol Psychiatry. 1998; 22(7): 1217-40.
Kim GW, Copin JC, Kawase M, Chen SF, Sato S, Gobbel GT, et al. Excitotoxicity is required for induction of oxidative stress and apoptosis in mouse striatum by the mitochondrial toxin, 3-nitropropionic acid. J Cereb Blood Flow Metab. 2000; 20(1): 119-29.
Szabó A, Papp A, Nagymajtényi L. Effects of 3-nitropropionic acid in rats: general toxicity and functional neurotoxicity. Arh Hig Rada Toksikol. 2005; 56(4): 297-302.
Kumar P, Kumar A. Effect of lycopene and epigallocatechin-3-gallate against 3-nitropropionic acid induced cognitive dysfunction and glutathione depletion in rat: a novel nitric oxide mechanism. Food Chem Toxicol. 2009; 47(10): 2522-30.
Jang M, Lee MJ, Cho IH. Ethyl pyruvate ameliorates 3-nitropropionic acid-induced striatal toxicity through anti-neuronal cell death and anti-inflammatory mechanisms. Brain Behav Immun. 2014; 38: 151-65.
Borlongan CV, Koutouzis TK, Randall TS, Freeman TB, Cahill DW, Sanberg PR. Systemic 3-nitropropionic acid: behavioral deficits and striatal damage in adult rats. Brain Res Bull. 1995; 36(6): 549-56.
Domenici MR, Chiodi V, Averna M, Armida M, Pèzzola A, Pepponi R, et al. Neuronal adenosine A(2A) receptor overexpression is neuroprotective towards 3-nitropropionic acid-induced striatal toxicity: a rat model of Huntington's disease. Purinergic Signal. 2018; 14(3): 235-43.
Sidhu A, Diwan V, Kaur H, Bhateja D, Singh CK, Sharma S, et al. Nicotinamide reverses behavioral impairments and provides neuroprotection in 3-nitropropionic acid induced animal model ofHuntington's disease: implication of oxidative stress- poly(ADP- ribose) polymerase pathway. Metab Brain Dis. 2018; 33(6): 1911-21.
Ramachandran S, Thangarajan S. Thymoquinone loaded solid lipid nanoparticles counteracts 3-Nitropropionic acid induced motor impairments and neuroinflammation in rat model of Huntington's disease. Metab Brain Dis. 2018; 33(5): 1459-70.
Orozco-Ibarra M, García-Morales J, Calvo-Silva FJ, Fernández-Valverde F, Serrano-García N. Striatal mitochondria response to 3-nitropropionic acid and fish oil treatment. Nutr Neurosci. 2018; 21(2): 132-42.
Calderón Guzmán D, Osnaya Brizuela N, Ortiz Herrera M, Juárez Olguín H, Valenzuela Peraza A, Hernández García E, et al. Folic acid increases levels of GHS in brain of rats with oxidative stress induced with 3-nitropropionic acid. Arch Physiol Biochem. 2020; 126(1): 1-6.
Park JE, Lee ST, Im WS, Chu K, Kim M. Galantamine reduces striatal degeneration in 3-nitropropionic acid model of Huntington's disease. Neurosci Lett. 2008; 448(1): 143-7.
Ouary S, Bizat N, Altairac S, Ménétrat H, Mittoux V, Condé F, et al. Major strain differences in response to chronic systemic administration of the mitochondrial toxin 3-nitropropionic acid in rats: implications for neuroprotection studies. Neuroscience. 2000; 97(3): 521-30.
Alexi T, Hughes PE, Knüsel B, Tobin AJ. Metabolic compromise with systemic 3-nitropropionic acid produces striatal apoptosis in Sprague-Dawley rats but not in BALB/c ByJ mice. Exp Neurol. 1998; 153(1): 74-93.
Gabrielson KL, Hogue BA, Bohr VA, Cardounel AJ, Nakajima W, Kofler J, et al. Mitochondrial toxin 3-nitropropionic acid induces cardiac and neurotoxicity differentially in mice. Am J Pathol. 2001; 159(4): 1507-20.
Klivenyi P, Andreassen OA, Ferrante RJ, Dedeoglu A, Mueller G, Lancelot E, et al. Mice deficient in cellular glutathione peroxidase show increased vulnerability to malonate, 3-nitropropionic acid, and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. J Neurosci. 2000; 20(1): 1-7.
Henshaw R, Jenkins BG, Schulz JB, Ferrante RJ, Kowall NW, Rosen BR, et al. Malonate produces striatal lesions by indirect NMDA receptor activation. Brain Res. 1994; 647(1): 161-6.
Greene JG, Porter RH, Eller RV, Greenamyre JT. Inhibition of succinate dehydrogenase by malonic acid produces an “excitotoxic” lesion in rat striatum. J Neurochem. 1993; 61(3): 1151-4.
Sagredo O, González S, Aroyo I, Pazos MR, Benito C, Lastres-Becker I, et al. Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease. Glia. 2009; 57(11): 1154-67.
Valdeolivas S, Pazos MR, Bisogno T, Piscitelli F, Iannotti FA, Allarà M, et al. The inhibition of 2-arachidonoyl-glycerol (2-AG) biosynthesis, rather than enhancing striatal damage, protects striatal neurons from malonate-induced death: a potential role of cyclooxygenase-2-dependent metabolism of 2-AG. Cell Death Dis. 2013; 4(10): e862.
Kalonia H, Kumar P, Kumar A, Nehru B. Protective effect of montelukast against quinolinic acid/malonic acid induced neurotoxicity: possible behavioral, biochemical, mitochondrial and tumor necrosis factor-α level alterations in rats. Neuroscience. 2010; 171(1): 284-99.
Kumar A, Sharma N, Mishra J, Kalonia H. Synergistical neuroprotection of rofecoxib and statins against malonic acid induced Huntington's disease like symptoms and related cognitive dysfunction in rats. Eur J Pharmacol. 2013; 709(1-3): 1-12.
Toulmond S, Tang K, Bureau Y, Ashdown H, Degen S, O'Donnell R, et al. Neuroprotective effects of M826, a reversible caspase-3 inhibitor, in the rat malonate model of Huntington's disease. Br J Pharmacol. 2004; 141(4): 689-97.
Schwarcz R, Coyle JT. Striatal lesions with kainic acid: neurochemical characteristics. Brain Res. 1977; 127(2): 235-49.
Coyle JT, Schwarcz R. Lesion of striatal neurones with kainic acid provides a model for Huntington's chorea. Nature. 1976; 263(5574): 244-6.
Sanberg PR, Lehmann J, Fibiger HC. Impaired learning and memory after kainic acid lesions of the striatum: a behavioral model of Huntington's disease. Brain Res. 1978; 149(2): 546-51.
Deckel AW, Robinson RG, Coyle JT, Sanberg PR. Reversal of long-term locomotor abnormalities in the kainic acid model of Huntington's disease by day 18 fetal striatal implants. Eur J Pharmacol. 1983; 93(3-4): 287-8.
Zeron MM, Hansson O, Chen N, Wellington CL, Leavitt BR, Brundin P, et al. Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron. 2002; 33(6): 849-60.
Arregui A, Emson PC, Spokes EG. Angiotensin-converting enzyme in substantia nigra: reduction of activity in Huntington's disease and after intrastriatal kainic acid in rats. Eur J Pharmacol. 1978; 52(1): 121-4.
Stoy N, Mackay GM, Forrest CM, Christofides J, Egerton M, Stone TW, et al. Tryptophan metabolism and oxidative stress in patients with Huntington's disease. J Neurochem. 2005; 93(3): 611-23.
Schwarcz R, Guidetti P, Sathyasaikumar KV, Muchowski PJ. Of mice, rats and men: Revisiting the quinolinic acid hypothesis of Huntington's disease. Prog Neurobiol. 2010; 90(2): 230-45.
Smith AJ, Stone TW, Smith RA. Neurotoxicity of tryptophan metabolites. Biochem Soc Trans. 2007; 35(Pt 5): 1287-9.
Pintor A, Tebano MT, Martire A, Grieco R, Galluzzo M, Scattoni ML, et al. The cannabinoid receptor agonist WIN 55,212-2 attenuates the effects induced by quinolinic acid in the rat striatum. Neuropharmacology. 2006; 51(5): 1004-12.
Pérez-De La Cruz V, Elinos-Calderón D, Robledo-Arratia Y, Medina-Campos ON, Pedraza-Chaverrí J, Ali SF, et al. Targeting oxidative/nitrergic stress ameliorates motor impairment, and attenuates synaptic mitochondrial dysfunction and lipid peroxidation in two models of Huntington's disease. Behav Brain Res. 2009; 199(2): 210-7.
Kalonia H, Kumar P, Kumar A. Attenuation of proinflammatory cytokines and apoptotic process by verapamil and diltiazem against quinolinic acid induced Huntington like alterations in rats. Brain Res. 2011; 1372: 115-26.
Mishra J, Kumar A. Improvement of mitochondrial NAD(+)/FAD(+)-linked state-3 respiration by caffeine attenuates quinolinic acid induced motor impairment in rats: implications in Huntington's disease. Pharmacol Rep. 2014; 66(6): 1148-55.
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Chronic Diseases Journal
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.
